Post by ICON plc

Oligonucleotide (ON) drug development is accelerating rapidly—but first‑in‑human (FIH) studies remain complex. Listen to our recent webinar where specialists discussed: - Translational PK/PD and toxicity considerations - FIH study design and population selection - Safety mitigation strategies (sentinel dosing, escalation, follow‑up) - Immunogenicity and QT‑prolongation assessment https://ow.ly/iJjg50ZbN0U #Learning #DrugDevelopment #ClinicalTrials #ONTherapeutics